Measurements of nuclear cross-section of production of theranostic radionuclides at LASA laboratory in Italy: focus on terbium quadruplet

Radionuclides and radiopharmaceuticals play a pivotal role in modern nuclear medicine, enabling both diagnostic imaging and targeted therapeutic interventions. The evolving landscape of radiation applications in nuclear medicine, including the emergence of theranostics, bimodal imaging, and targeted radiotherapy, underscores the urgent need for novel radionuclides with diverse chemical and physical characteristics. Drawing upon decades of experience, the Milano team has been at the forefront of radionuclide production for medical applications, leveraging state-of-the-art facilities at LASA laboratories in collaboration with institutions such as JRC-ISPRA (Ispra, Italy) and GIP ARRONAX2 (Saint-Herblain, FR). Over the years, their efforts have encompassed the investigation of more than 70 radionuclides, with a concerted focus on advancing the theranostic paradigm, a holistic approach that integrates therapeutic and diagnostic stages utilizing a singular radiopharmaceutical entity.